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ABSTRACT
Both wild-type and mutated beta-amyloid (Aβ) peptides can elicit an immune
response when delivered subcutaneously. However, only mutated forms of Aβ can
sensitize dendritic cells when administered intravenously or intraperitoneally. To
understand the role of mutation and delivery routes in creating immune responses,
and the function of dendritic cells as therapeutic agents, we used fluorescentconjugated WT Aβ1-40 (WT40) and artificially mutated Aβ1-40 (22W40) peptides
to treat dendritic and Langerhans cells from young and/or old mice at different time
points. The cell types were analyzed by flow cytometry and confocal microscopy to
identify differences in function and antigen presentation, and Luminex and Western
blots for cell activation and associated mechanisms. Our results demonstrated that
the artificial mutant, 22W40, enhanced dendritic cell’s phagocytosis and antigen
presentation better than the WT40. Interestingly, Langerhans cells were more
effective at early presentation. The artificial mutant 22W40 increased CD8α+ dendritic
cells, CD8+ T-cells, and IFN-γ production when co-cultured with self-lymphocytes and
dendritic cells from aged mice (30-month-old). Here, the 22W40 mutant peptide has
been found to be potent enough to activate DCs, and that dendritic cell-based therapy
may be a more effective treatment for age-related diseases, such as Alzheimer’s
disease (AD).

INTRODUCTION

into the subject to induce an antibody response to the
injected antigen. This method was originally designed
for prophylactic purposes because it requires incubation
period, about 2 weeks [1] and even longer for the elderly
[2, 3],to generate protection. Therefore, vaccination is
generally not used while the person is already affected
by the pathogen. However, antibody therapy, otherwise
known as passive immunotherapy, aims to deliver antibody

Immunotherapy has been widely implemented in
the treatment of various types of diseases, spanning from
foreign pathogens to autoimmune origins. Traditionally,
immunotherapies can be grouped as either vaccine or
antibody/anti-sera therapy. Vaccination, also known as
active immunotherapy, works by injecting an antigen
www.impactjournals.com/oncotarget
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or antisera into a subject who may be already affected by
the pathogen. Although passive immunotherapy works
ideally for those already showing disease symptoms, long
term use of this method can induce serum sickness, where
the body produces antibodies against the injected sera.
In addition, the relatively high cost associated with this
method limits its preference.
With advancements in technology, vaccination
methods have been expanded to treat many other
diseases such as cancer, diabetes, and arthritis. An HPV
vaccine that was recently licensed is currently making
strides at eliminating HPV-derived cervical cancers
[4]. Almost a decade ago, there was a breakthrough in
neurodegenerative disease vaccine development when
Elan pharmaceutical launched the first clinical trial of
Alzheimer’s vaccine developed from Aβ peptide plus a
strong adjuvant. Although the clinical trial was suspended
by the FDA due to strong adverse effects [5, 6], the
fundamental work opened a new era for immunotherapies
against neurodegenerative diseases. Currently, the idea
of immunotherapy has been extended to any therapy that
works via modulation of the immune system, and from
this, we are starting to see vaccines become less of a
prophylactic measure to more of a treatment procedure.
Cell-based immunotherapies have become a
dominant therapeutic method for cancer because of its selfdonor property. Based on this same property, the approach
has been evaluated for AD treatment in mouse model [7,
8]. With progress in knowledge on dendritic cells, more
potent therapeutic vaccines have been developed for use in
disease treatment. Dendritic cells (DCs) are considered as
the professional antigen presenting cells (APC), and play
a very critical role in antigen presentation to the immune
system. They also serve as mediators between the innate
immune system and the adaptive immune system. The
role of APCs in neurodegenerative diseases is scarcely
studied, and so, understanding the role and properties of
DCs in AD will help us better unravel the mechanism for
Alzheimer’s disease progression, thus hopefully leading
to a solution.
Both mature and immature DCs can be found in
the circulatory system; they are specialized for antigen
uptake, procession and presentation to T-cells [9, 10].
For a long time, immunologists have believed that DCs
from peripheral blood were the same as those residing
in the skin, known as Langerhans cells (LCs). However,
DCs in the blood comprise of both mature and immature
phenotypes, whereas Langerhans cells (LCs) are immature
cells of the DC system. LCs also take up antigens, but
only in the epidermis. In addition, DCs and LCs carry
different surface markers, implying that they may have
different functions. Antigen-stimulated DCs and LCs
migrate to secondary lymphoid organs to stimulate T-cells,
and initiate an immune response. A recent discovery of
the existence of lymphatic system in the brain is an
impetus for DCs based vaccine for brain diseases [11]. As
www.impactjournals.com/oncotarget

originally discovered by Alois Alzheimer, the brain of an
AD patient is overwhelmed with Aβ-42/43 peptide plaque
buildup [12]. This extracellular protein inspired the use
of the misfolded molecules, contained in the plaques, as
the antigen component of a vaccine. It was discovered
that Aβ1-42 peptide contained two very strong B cell
epitopes [13], and one major T-cell epitope [14, 15]. It is
interesting to note that beta-amyloid peptide sequence is
highly conserved among mammalian species [16], thus a
prompt that it might have important biological function(s),
although this is/ are yet to be precisely elucidated [17]. Not
with standing, the peptide has been reported to show some
protection against oxidative stress in the brain [18, 19], to
aid in cholesterol transport [20], and have antimicrobial
activity [21, 22]. The Aβ peptide alone has been shown to
induce antibody response, without the use of an adjuvant
[23]. This indicates that Aβ1-42 is very immunogenic
and may play very important role in immune balance
or tolerance. Interestingly, known human mutations in
the T-cell epitope of Aβ have been linked to different
clinical symptoms: patients with the Dutch mutation
predominantly show hemorrhaging in the brain [24, 25],
while patients with the Flemish mutation demonstrate
both AD-like amyloid deposition and hemorrhaging [26].
It has also been suggested that these mutations in the
T-cell epitope enhanced the production of Aβ plaques, and
therefore may be directly related to the early onset of the
disease [27, 28]. In fact, when mutant Aβ peptide was used
as vaccine, it showed more immunogenicity than the wildtype form [29].
Currently, many cell-based vaccines use peptidesensitized DCs with less focus on LCs. However, most
vaccines used for disease prevention are delivered via
intradermal injection, and work through the activation
of LCs. Thus, it is extremely important to understand
the differences between how DCs and LCs work, upon
antigen stimulation, when used in vaccination. In our
previous study, we proved that the WT form of Aβ
peptide is immunogenic and even more profound was
the immunogenicity of the mutant variants (Flemish
and Dutch) [29]. When we used wild-type and mutant
peptide-sensitized DCs as vaccines, cells sensitized with
only the mutant peptides could induce antibody response
without triggering inflammation [14]. Meanwhile, when
the same peptides were subcutaneously injected into mice,
both the wild-type and mutant forms induced antibody
response [30, 31]. This interesting observation prompted
in us the idea that the same peptide may act differently in
the body, depending on the route of administration, and
that verifying this phenomena may help in finding and
developing safe and effective vaccines.
In line with this, we sensitized bone marrow-derived
DCs (BMDCs) and skin-isolated Langerhans cells (LCs)
with wild-type and mutant (mutated T-cell epitope, which
ranges from among amino acids 17 to 24, using both
known human and artificial mutations) Aβ peptides to
35444
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investigate the significance of mutation and delivery route
in vaccine development.

however, did not show any significant differences between
the groups (Figure 5A, right graph). This indicates
increased uptake activity of DC cells when challenged
with 22W mutant peptide as compared with either control
or WT peptides. The percentage of peptide+CD8α+(doublepositive) cells was significantly higher in the mutated
group among all peptide groups at all-time points in the
DC culture (Figure 5B, left graph). Though in the LC
grouping, significant differences were found between
the 22W and the control, and the 22W versus the WT
peptides at 12h and 24h, none was found between the
control vs. the WT peptides at either time point (Figure
5B, right graph). The percentage of CD4+ cells showed
no significant differences among all the groups and time
points for either the DC or LC groupings (Figure 5C).
Finally, we measured the concentration of IFN-γ in the coculture supernatant. There were significantly higher levels
in 22W-DC samples than in WT-DC at 24h time point, and
higher levels in the 22W-LC than in the control-LC during
the same period (Figure 5D).

RESULTS
Antigen presentation ability of BMDCs in
youngC57/B6 mice shows no difference between
florescent labeled wild-type and mutant Aβ1-40
peptide
We used bone marrow derived dendritic cells from
2 months old C57/B6 mice, and sensitized them with
florescent labeled wild and artificially mutated 22WAβ140 peptides. We then analyzed MHC class II and Aβ
expression levels at two different time points (12h and
24h). There was no significant difference in the levels of
both MHC II and Aβ on DCs treated with either the mutant
or wild-type peptide (P > 0.05, n = 4)(Figure 1A and 1B).
To further verify this, we employed confocal microscopy
to visualize the location of the antigens. By fluorescence,
there seem to be more MHC II/CD11c localization on DCs
stimulated with mutant Aβ peptides (Figure 2).

Aged mice have the ability to differentiate DC,
and mutated peptide better sensitize them
After demonstrating the existence of differential
antigen presentation by DCs of young mice, we wanted
to know the functional activity of these cells in older
mice with regards to antigen presentation. Using the
same approach as in the young mice, we discovered
that older mice (30-months old) still had functional DCs
with able antigen presentation ability (Figure 6). Also,
the percentages of CD11c+peptide+ double-positive cells
(Figure 6A), CD8α+ cells (Figure 6B), MHCII+peptide+
double-positive cells (Figure 6C), and MHCII+CD8α+
double-positive cells (Figure 6D) were significantly higher
in 22W-mutant DCs than in WT or control peptide treated
DCs (n = 4, P < 0.05).
We also included an Aβ 42-1 peptide, a reverse
of the normal Aβ 1-42 peptide sequence, as a control
antigen to stimulate the DCs from old mice. This was to
help clarify whether the observed antigen response was
Aβ-specific or just a general antigenicity response due
to declined immune function. We discovered that only
the Aβ 1-40 WT and Aβ 1-40 22W could successfully
sensitize DCs (Figure 7 A, 7B, 7C). There were significant
differences in percentages of CD8α+ cells (Figure 7B) and
MHCII+CD8α+ double-positive cells (Figure 7C). The
22W mutant peptide significantly activated these aged
DCs than any other peptide treatment in this study.

Langerhans cells (LCs) from young C57/B6
mice show significant differences in antigen
presentation ability between florescent labeled
wild-type and mutant Aβ1-40 peptide
When LCs were treated with the same peptide
regimen as the DCs, significant differences in the levels
of both MHC II and Aβ peptide uptake were observed in
a time-dependent manner (Figure 3A, 3B). Additionally,
significantly higher double positive cells for CD207 and
MHCII were observed (n = 4, P < 0.05). There were also
significant differences in the mean fluorescent intensity
(MFI) in the 22W mutant peptide-treated group than their
wild-type cohort (n = 4, P < 0.05). Confocal microscopy
confirmed this observation (Figure 4).

The differences of antigen presentation and T cell
activation between DCs and LCs
To identify the ability of antigen presentation,
antigen sensitized DCs or LCs were co-cultured with
splenocytes. DCs and LCs were allowed 12 and 24 hours
to uptake either the control, WT or 22W peptides in a
cell culture and then co-cultured with splenocytes. Cell
surface marker analysis on these various cells by flow
cytometry revealed that the percentage of CD8α+ cells
was higher in the 22W-stimulated DC-splenocytes coculture group as compared with the control group after 24
hours of incubation (Figure 5A, left graph). The LC group,
www.impactjournals.com/oncotarget

No differences in inflammatory cytokine secretion
by antigen sensitized DCs
There were significant immune response differences
when Aβ1-40WT and Aβ1-40 22W were used to sensitize
35445
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Figure 1: Antigen presentation results of DCs sensitized by wild-type FAM-Aβ 1-40 (WT FAM-Aβ 1-40), and FAMAβ40 carrying mutation at aa22 (22W FAM-Aβ 1-40). A., Harvested DCs were identified as MHC class II+ and CD11c+ cells

using flow cytometry assay after staining with different florescent conjugated antibodies. A (top) is the flow cytometry diagram for antigen
stimulated DCs at different time points. Graphs in B. demonstrate the percentage of MHCII (top row) or CD11c (bottom row) in the peptide
double positive DCs, the mean fluorescent intensity (MFI) of the peptide in the double positive DCs (middle), and the MFI of the MHCII
(top right) or the CD11c (bottom right) in the double positive DCs. There is no statistical significant differences between two antigens (P
> 0.05, n = 4).
www.impactjournals.com/oncotarget

35446

Oncotarget

DCs as a vaccine. To investigate the role of specific cell
population in the immune response, we examined cytokine
production by DCs from mice of different genotypes
(Figure 8). Overall, there was no significant, but just
marginal, differences attributed to genotype and peptide
stimulation (n = 4, P > 0.05).

About 15 years ago, injection of a novel Aβ
peptide vaccine generated great interest in the fields of
neuroscience and AD, showing promise in basic research
but this was suspended in clinical trial due to adverse
effects. Recently, our lab developed a novel and safe
vaccine against AD using peptide-sensitized DCs [14,
41-44]. Since then, we have also focused and established
a BMDC culture method and repeatedly tested our
peptide-sensitized DCs as a therapeutic vaccine for AD.
The purity of the DCs derived with this method can be
more than 95% when detected with MHCII and CD11c as
markers [14, 41, 42]. In the vaccine development process,
we also noticed that WT and mutated (22W) Aβ could
induce immune response when delivered by subcutaneous
injection, with or without an adjuvant. However, the WT
peptide failed to induce the same response when used to
sensitize DCs alone, and that all peptides with a mutated
T cell epitope could induce antibody response, thus the
reason for focusing on 22W peptide only in this study. We
also investigated difference in activation of DCs and LCs
by the wild type and mutant type peptides.
To elucidate the function of our artificial mutant
peptide in DCs sensitization and the differences between
BMDCs and LCs, we conducted several experiments on
both young and old mice to evaluate the function of these
cells in order to address this age related disease (AD).
There was no significant difference in antigen presentation
(Aβ florescence) or MHCII expression level between wildtype and mutant peptide-sensitize DCs (Figure 1A, 1B),
but we did observed slightly more fluorescence from the
mutant peptide-treated cells (Figure 2). Our hypothesis
is that no difference was observed between the WT and
22W mutant peptides because of the relatively young age
of the mice. At this age, the immune system is in its prime,
and that both peptides are processed with high efficiency.
Based on our lab’s previous experience, there should
be a difference in antigen presentation between the two

Peptide sensitized DCs vaccine rely on the
mutated T cell epitope but not the MHCI affinity
and peptide aggregation
Western blot analysis was performed on a number
of different peptides based on different mutations in beta
amyloid (Figure 9). The lowest affinity mutations (24M
mutation) showed the highest levels of aggregation
(Lanes 12-14), and the WT (Lanes 1-4) had higher proaggregation property compared with 22W mutant (Lanes
9-11), as demonstrated by the number of oligomer
isoforms from the Western blot. The WT form of Aβ also
showed much lower affinity for MHC Class I.

DISCUSSION
Many studies have reported the link that exists
between the immune system and neurological disease,
including AD [32-35]. Currently, mounting research have
focused on immunotherapies and T-cell therapy as major
approaches to treating these disorders [7, 8, 36]. It has
been suggested that targeting the immune system may be
the safer and more effective treatment approach for AD
[37, 38]. With regards to this treatment, dendritic cells
(DCs) are the favorable cell types used in immunotherapy,
because they can modulate both the innate and acquired
immune systems with autologous cells, and because of
this, is currently being used exponentially in treatment of
disease, such as cancer [39, 40].

Figure 2: Confocal microscopy images of DCs sensitized by WT and mutant (22W) peptides. BMDCs have the ability to

uptake and present antigens on the cell surface. The florescent level here is used as indicator for level of antigen presentation. Cells treated
the same as in flow cytometry assay, and attached onto slide by cytospin assay: BMDCs stained for MHC-II/CD11c (red fluorescence),
incorporated FAM-Aβ40 (green fluorescence). A. shows in vitro uptake of FAM-Aβ40 WT (top) or 22W (bottom) by cultured BMDCs and
the corresponding MHC II levels, where B. shows CD11c levels in response to WT (top) or 22W (bottom). In both columns, it seems as if
there more localization of MHCII/CD11c with Aβ in mutant peptide-sensitize cells than the wild-type peptide-sensitize cells.
www.impactjournals.com/oncotarget
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Figure 3: Antigen presentation results of LCs sensitized by wild-type FAM-Aβ 1-40 (WT FAM-Aβ 1-40), and FAMAβ40 carrying mutation at aa22 (22W FAM-Aβ 1-40). A., Harvested LCs were identified as MHC class II+ and CD11c+ cells
using flow cytometry assay after staining with different florescent conjugated antibodies. A is the flow cytometry diagram for antigen
stimulated LCs at different time points. Graphs in B. demonstrate the percentage of MHCII (top left) or CD207 (bottom left) in the peptide
double positive LCs, the mean fluorescent intensity (MFI) of the peptide in the double positive LCs (middle), and the MFI of the MHCII
or the CD207 in the double positive LCs. There are significant higher positive cell percentages) and MFI of peptide inside the cells in the
mutant peptide treated group than the wild-type peptide treated group (n = 4, P < 0.05) for both the MHCII and CD207 double positive
cells. However, the significances vary for the middle column of graphs comparing the levels of MHCII in the MHCII cells and the levels
of CD207 in CD207 cells.
www.impactjournals.com/oncotarget
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peptides when mice are treated more frequently and over
a longer period of time [31].
When these same peptides were tested in much
older mice (30 month old, (Figure 6), the 22W mutant
peptide strongly sensitized DCs than WT peptide (Figure
7). Here, we assert that possibly, the 22W mutant peptide
elicited such higher response because it could break DCs’
tolerance to Aβ peptides.
Age-related diseases, like AD, show impaired
immune function [45, 46], and the immune response in
older subjects will most likely be too weak for the body
effectively recognize antigens. Therefore when designing
a vaccine, a strong adjuvant is usually introduced to help
elicit the immune response. This sometimes is too strong
in effect, causing massive adverse side-effects as seen in
the original Elan pharmaceutical’s vaccine for AD. In our
study, we have used peptides to sensitize older, 30 month
old, mice and our result showed that they effectively
sensitize DCs, and more importantly convert to CD8α+
cells. The CD8α+ cells can then expand and enhance CD8+
T-cell population, causing a strong antiviral and bacterial
response. CD8+ or cytotoxic T-cells plays critical role
in fighting infectious disease and cancer, and as older
patients are more susceptible to all kinds of infection, this
DC vaccine may have unique overlapping benefits.
When LCs from young mice were examined under
the same regimen as the DCs, the mutant 22W peptide
elicited significantly stronger immune response compared
to the WT peptide (P < 0.05, Figures 3A, 3B, and 4). This
result was noticeably different from that of DCs, as the
LCs seemed to respond better to the mutant peptide in
young mice. This observation we explain to be tolerance
related. LCs reside in the epidermis, papillary dermis, and
mucosa and carry out specific homeostatic function [47,
48] and may have little or no prior exposure to a fairly
unseen antigen in the epithelia, the Aβ peptide. Therefore,

they are less likely to develop tolerance to the peptide,
and thus can be readily activated/sensitized by the peptide.
On the other hand, DCs which are within the peripheral
circulatory system more often encounter peripheral Aβ in
the blood and are able to easily/ quickly develop tolerance
to this peptide
When LCs and DCs were co-cultured with
splenocytes, there was increased uptake in the DC
population of 22W than the WT (Figure 5). There was
also an increase in CD8α+ cells from the DC co-culture,
but not the LC co-culture, and a corresponding increase in
the peptide+CD8α+ double positive co-culture (significant
across all levels of measurement) and also of the LCs
(significant only when comparing the 22W to either the
WT or control). We also see LCs as being slightly more
potent than DCs here in terms of antigen presentation on
the bases of percentage positive cells. However, there
were no differences in the population of CD4+ cells
(Figure. 5C). IFN-γ concentrations in the supernatants
from the co-cultures, revealed higher levels in the 22W
peptide co-cultures of both DCs and LCs at 24 hours.
This is very essential in the demonstration that the mutant
peptide promotes cellular, rather than humoral, response
as evidenced by the increase in CD8+ T-cells and IFN-γ
production.
One of the major concerns for immunotherapy is
the safety of treatment because of the close link between
inflammation and AD. The effect of most vaccinations
is to prime the immune system, but an overtly strong
response can be life-threatening to the patient. To test
the safeness of the immune response, we assessed a
panel of humoral and cellular induced cytokines and
chemokines to validate the DC vaccine. Cytokine and
chemokine expression profile analysis showed that there
were no significant changes across the panels (Figure 8).
This suggests that our DC-based vaccine may not induce

Figure 4: Confocal microscopy pictures of LCs sensitized by different peptides.LCs have the ability of uptake and
present antigens on the surface. The florescent level here is used as indicator for antigen presentation. Cells treated the same as in flow

cytometry assay, and attached onto slide by cytospin assay: LCs stained for MHC-II/CD11c (red fluorescence), incorporated FAM-Aβ40
(green fluorescence). The left column of A. demonstrated in vitro uptake of FAM-Aβ40 WT (top-left) or 22W (bottom-left) by cultured
LCs and studied for MHC-II expression. There seems to be more localization of MHCII with Aβ in mutant peptide-sensitize cells than the
wild-type peptide-sensitize cells. The right column of B. shows the CD11c expression and Aβ level uptake in the same cell type stimulated
with different peptides, either the WT (top) or 22W (bottom) Aβ. There is more CD11c expressed and more antigen in the cell in the mutant
peptide-sensitize LCs than in wild-type peptide-sensitize LCs.
www.impactjournals.com/oncotarget
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Figure 5: Result of antigen stimulated Dendritic cell (DC) or Langerhans cell (LC) co-cultured with splenocytes. When

DCs and LCs were prepared from the mouse, the splenocytes were also harvested and frozen. The antigens were presented and allowed
for uptake by the cells. Two days after the antigen stimulation to DCs and LCs, the splenocytes were thawed and placed in the incubator
overnight. The cells were then co-cultured together on the third day, and cells were harvested next day and an antibody cocktail was used
to stain the cells. In A., the percentage of CD8a+ DCs and LCs when co-cultured with splenocytes at 12h and 24h. At 24 hours, there was
significant percentage changes in the DCs-splenocytes co-cultured group between two peptides (mutant higher than wild-type and control,
n = 4, P < 0.05) and there is no differences seen in LCs-splenocyte co-cultured group between two peptides at either time point. In B., the
percentage of peptide+ cells in CD8a+ cells was measured in the DCs and LCs co-cultured at 12h and 24h. Significances were found for
both LCs and DCs cultures between the control, WT, and mutant peptides (n = 4, P < 0.05), except for when comparing the control and WT
groups in LCs (P > 0.05). In C., the percentage of CD4+ T-cells were studied in the DCs and LCs co-cultures with splenocytes at 12h and
24h. No significances were found. In D., the concentration of IFN-gamma was studied in the co-culture system at 12 hours and 24 hours.
There is a significant difference in the DC population between the control and mutant antigen at the 24h time point (n = 4, P < 0.05). There
is also a significance between the mutant and control antigen in the LC population (n = 4, P < 0.05).

Figure 6: Antigen presentation by DC cells from different genotypes of 30 month old mice. The percentage of the
CD11c+peptide+ double positive A., CD8a+ B., MHCII+peptide+ double positive C., and MHCII+CD8a+ double positive D cell types
were studied after antigen stimulation to DCs cells from non-transgenic (NT) mice, APP, and APP/PS1 mice genotypes (n = 4 per group). In
studying the CD11c+ cells A., we found significance between the WT and mutant (22w) in the NT mouse genotype only (n = 4, P < 0.05).
However, significance was found in all three mouse genotypes, between the levels of WT and 22w Aβ, in the percentages of CD8a+ cells
B., in the percentages of MHCII+peptide+ cells C., and in the percentages of MHCII+CD8a+ cells D. (n = 4, P < 0.05).
www.impactjournals.com/oncotarget
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Figure 7: Cell marker induction shows antigen specificity in 30 month old APP/PS1 mice. MHCII+ and CD8a+ Dendritic

cells (DCs) in the aged mice were studied by flow cytometry (not shown) after antigen stimulation for 24 hours. There was no significant
difference when looking at the percentage uptake of MHCII+ DCs in terms of the different peptides A.. However, significant differences
were found in B., when looking at the differences in CD8a+ DCs between the mutant peptide and all over levels (P < 0.05). In C., significant
differences were also found in CD8a+ , MHC-II+ double positive DCs when comparing the mutant peptide to all over levels (P < 0.05).

Figure 8: Result of cytokine and chemokine expression profile after antigen stimulation to DCs from different genotype
mice. Various cytokine levels of dendritic cells (DCs) were detected with Luminex multiplex assay 24 hours after Aβ1-40 WT or Aβ1-40
22w stimulation. The cytokines IL4, IL6, IL10, IFN-gamma, TNF-alpha, and G-CSF levels were measured from DCs cell supernatant of
non-transgenic mice (NT) A. and APP/PS1 mice B. There are no significant differences found among any of the groupings (n = 4, P > 0.05).
www.impactjournals.com/oncotarget
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Figure 9: Western Blot results of different types of peptide treatment. Shown is the Western Blot result for different mutations
in the beta amyloid peptide. The lanes for the western blot result are as follows (all reconstituted from HFIP treated film): Lane 1, WT Aβ
without aggregation; Lane 2-4, WT Aβ aggregated for 3 hr, 16 hr, and 24 hr at 37 °C; Lane 5, Aβ with Dutch mutation without aggregation;
Lane 6-8, Aβ with Dutch mutation aggregated for 3 hr, 16 hr, and 24 hr at 37 °C; Lane 9, Aβ with a 22W mutation without aggregation;
Lane 10-11, Aβ with a 22W mutation aggregated for 16 hr and 24 hr at 37 °C; Lane 12, Aβ with a 24M mutation without aggregation; Lane
13-14, Aβ with a 24M mutation aggregated for 16 hr and 24 hr at 37 °C. On the right are the MHC Class I affinity results for each of the
different mutations. Each of the rows is as follows: From Top to Bottom, Wild-type, Flemish, Dutch, PFDM, 22W, and 24M.

MATERIALS AND METHODS

excessive inflammation.
The DC activation, in our experiment, is believed to
be MHC-I affinity dependent but not specifically peptide
conformation related (Figure 9). The lowest affinity
mutations (24M mutation) showed the highest levels of
aggregation (Lanes 12-14, Figure 9); the WT (Lanes 1-4)
demonstrated much pro-aggregation than 22W (Lanes
9-11). The WT form of Aβ was also much lower in terms
of MHC Class I affinity and failed to sensitize DCs
when tested in both BALB/c and APP/PS1 as compared
with 22W peptide. Inferentially, mutant peptides are
likely to effectively activate CD8+ T-cells. Also the
previous notions, that the WT form of Aβ is the largest
pro-aggregation form, might not be entirely true, as we
have demonstrated that the larger levels of aggregation
were exhibited by the mutant peptide (lanes 12 to 14) by
Western blot.
Our data from DCs and LCs sensitized with different
antigens have demonstrated that (1) BMDCs from older
mice can be sensitized with a specific antigen to facilitate
normal presentation function; peptide-sensitized DCs can
be a very potent and effective therapeutic vaccine in agerelated diseases when treated with the proper antigen, (2)
mutant Aβ peptide can stimulate CD8α+ DCs at a much
higher level; this novel function may boost immune
activity and help AD patients to withstand progressing
AD symptoms. These 22W peptide-treated DCs may be
used as a safe and effective vaccine method for AD, (3)
LCs have a quicker and stronger response to the antigen
than DCs; LCs and DCs may have different function in
immune reaction, and (4) the differences in sensitization
of DCs and LCs to WT and mutant peptides can be utilized
for future vaccine design.
www.impactjournals.com/oncotarget

Animals
Adult (8-week-old) male C57/B6 non-transgenic
littermate from APP/PS1 breeding colonies were used. All
mice were initially genotyped at the time of weaning, and
also before sacrifice. Additional confirmation was done
using plasma Aβ 40 level. Mice were housed under a 12
hr light-dark cycle, with ad libitum access to rodent chow
and water. All described procedures were approved by the
IACUC Committee of the University of South Florida. All
animals were housed in the vivarium at Byrd Alzheimer’s
Institute, Tampa, Florida.

Reagents
Florescent-labeled
peptides
(FAM-Aβ1-40,
FAM-Aβ1-40 with mutation at aa22, and Aβ42-1) were
purchased from Biomer Technology (CA, USA); all
antibodies for flow cytometry used in were purchased
from Biolegend Inc. (CA, USA). The antibodies were:
CD3,clone 17A2,CAT 100220;CD4,clone GK 1.5,CAT
100412; CD8a,clone 53-6.7,CAT 100708; CD205,clone
NLDC-145,CAT 138208; CD207,clone 4C7,CAT
144203; CD11c,clone N418,CAT 117310; MHC-II,
clone M5/114.15.2,CAT 107614; and IFN- γ, clone XMG
1.2,CAT 505810.
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Cells harvesting, dendritic cells differentiation
and cell culture

e. On the seventh day, 200 µl of supernatant was
carefully obtained from the DC well and stored in the
freezer. Peptide-sensitized DCs were collected and washed
with 1×PBS twice, then re-suspended with 1× PBS to
1×106 cells/ml. Next, splenocytes with DCs were mixed in
a 12 well plate. The proportion was 1:5, thus 0.6×106 DC
was mixed with 2.4×106 spleen cells per well.
f. On the eighth day, 200 µl supernatant was again
carefully collected from the DC culture, and then stored in
the freezer. Then, all cells were harvested and stained with
fluorescent labeled antibodies for FCM (flow cytometer)
and LSCM (laser scanning confocal microscope).

Dendritic Cells (DCs) preparation from mouse bone
marrow
DCs were harvested and prepared as previously
described [31]. In brief, non-transgenic mice littermates
(C57/B6) were euthanatized with carbon dioxide (CO2).
Leg bones were removed and placed in a dish containing
75% ethanol for 1 min and then washed twice with 1×PBS.
Bone ends were removed and the marrow cavity was then
flushed with 10% RPMI-1640 (RPMI containing 10%
FBS) medium. Aspirates were collected in a 50 ml conical
tube and then passed through a strainer to separate the
cells. The cells were pelleted by centrifugation at 400×g
for 10 min at 10 °C, and then 3ml of ACK buffer (160 mM
NH4Cl, 10 mM KHCO3 and 0.1 mM Na-EDTA) added
for 60s to lyse red blood cells (RBCs). Then cells were
resuspended in 30 ml of RPMI-1640 medium. Afterwards,
the cells were transferred to a 6 well-plate containing 3
ml 10% RPMI-1640 and reconstituted to 1×106 cells/ml
in RPMI 1640. Plate was incubated at 37 °C in a tissue
culture incubator.

Epidermal explant culture for LCs
We employed the method described by Sparber
et al. [49] with slight modification. Briefly, mouse
ears were removed at the base with scissors and rinsed
briefly in 75% ethanol, then air-dried on sterile gauze for
20 mins. The ears were split into the dorsal and ventral
halves (containing the cartilage) with two strong forceps
and then the dermal side placed downwards in 0.8%
trypsin solution for 25 mins. After 25mins, the tissue
was transferred onto a Petri dish containing 10ml pure
FBS. The epidermis was peeled off and the dermal piece
discarded. Epidermal pieces were then cultured in 3 ml
complete medium in 6-well plates for 3 days at 37oC.
Afterwards, the epidermal pieces were removed and the
emigrated cells were harvested from the culture medium.
Cells were centrifuged at 450×g for 5 min at 4oC and then
suspended appropriate medium for counting, and usage in
subsequent assays.

Isolation of splenocyte
Freshly acquired spleens were weighed, minced
and immediately pushed through a 40µm sieve to obtain a
mixed cell suspension. The suspensions were centrifuged
(350g, 5min) and supernatant discarded. ACK buffer was
added to lyse the red blood cells. 1×PBS was added to stop
the lysis, and the cells counted. The splenocyte suspension
was centrifuged (350g, 5min) again and suspended in
RPMI 1640 (Sigma-Aldrich) with 10% fetal calf serum
(Sigma-Aldrich), 10 u/ml IL-2.5µg/ml Con-A and 1%
β-mercaptoethanol, and incubated in 5% CO2, at 37℃ in
an incubator.

Sensitizing LC with Aβ peptides
Cells were cultured for 24 h in the CO2 incubator,
and then used for the following procedure:
On the first day, LCs were transferred into 12-well
plate (20×104cells per well).
After 72 h, 1 ml of culture media was removed and
replaced with fresh 10% RPMI 1640 containing 10ng/ml
GM-CSF and 10ng/ml IL-4. Then, wild type and mutant
type forms of Aβ peptides, as described earlier, were added
separately to a final concentration of 20μg/ml.
On the sixth day, 200µl of supernatant was carefully
collected from the LC well and stored. Afterwards, all
cells were harvested, and then stained with fluorescent
labeled antibodies for FCM and LSCM analyses.

Sensitization of DCs with Aβ peptides and co-culture
with splenocytes: DCs differentiation and maturation

a. On day zero, monocytes from bone marrow were
collected and cultured under 5% CO2in a 37oC incubator.
b. After 24 h, all supernatants were aspirated to
remove all non-adherent cells (lymphocytes, progenitors,
etc.). Cells were washed twice with 1XPBS gently. Then,
fresh 10% RPMI 1640, containing 10ng/ml murine GMCSF and 10ng/ml IL-4 (BD-Pharmgen, San Jose, CA) and
0.03% β-mercaptoethanol, was added.
c. On the fourth day, 1 ml of culture media was
removed and replaced with fresh 10% RPMI 1640
containing 10 ng/ml GM-CSF, 10 ng/ml IL-4. Wild,
mutant types of Aβpeptides and Aβ42-1 were added into
the designated well at a final concentration of 20 µg/ml.
d. On the sixth day, spleen cells were thawed, and
washed 3 times with 1XPBS. Afterwards, it was adjusted
to 2×106 cells/ml and cultured in an incubator.
www.impactjournals.com/oncotarget

Cytokines assay (Luminex)
Supernatants from co-cultures were stored at -80oC
after collection until used. A panel of 17 cytokines and
chemokines, including IFN-γ, IL-2, IL-4, IL-10, IL-12,
and TGF-β were measured using mouse multiplex kits
from Affymetrix science(CA, USA). Standard and all
samples were prepared according to the manufacture’s
protocol in a 96-well plate. The plate was read on a Bio35454
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PlxMagpix Luminex 200 reader (Bio-Rad, CA, USA), and
then the concentration of each analyte calculated based on
the generated standard curve.

Flow cytometry assay
All antibodies for cell labeling were purchased
from Biolegend (CA, USA). After 24-hour co-cultured
incubation, the cells were harvested and stained in a total
volume of 100 μl with 5μl different fluorescent labeled
antibodies. After 30 min of incubation at 4%, the cells
were fixed in 4% paraformaldehyde in 1×PBS solution.
The cells were washed twice in 1×PBS and detected with
a BD Accuri C6 Flow Cytometer (CA, USA).
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Confocal laser scanning microscope
All antibodies for cell labeling were purchased
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Statistical analysis
Data are expressed as the mean ± SD and analyzed
using one-way analysis of variance (ANOVA), followed
by Tukey post hoc test using Prism 6.0 (GraphPad
Software Inc., San Diego, CA). The level of statistical
significance was deemed to be P < 0.05.
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